Verismo Therapeutics
About:
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Website: https://verismotherapeutics.com
Twitter/X: VerismoTx
Top Investors: ScaleReady, BRV Capital Management, Hong Leong Bank, DongKoo Bio&Pharma
Description:
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer. Verismo’s cellular therapy, known as KIR-CAR, is designed to provide a “natural stimulation” to T cells without triggering the T-cell exhaustion for the treatment of solid tumors. The lead therapy candidates in preclinical development are targeting pancreatic cancer, mesothelioma, and ovarian cancer.
$40.2M
$1M to $10M
Philadelphia, Pennsylvania, United States
2020-01-01
info(AT)verismotherapeutics.com
Bryan Kim, Donald L. Siegel, Michael C. Milone
1-10
2024-09-17
Private
© 2025 bioDAO.ai